Close

Ratings by JPMorgan (Cory Kasimov)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
7/25/2022 Vertex VRTX Maintain Overweight
(N/A)
 
 
  Details
6/21/2022 Acadia Pharmaceuticals ACAD Downgrade Neutral
(Overweight)
19.51
(16.79)
-13.94% Details
6/15/2022 Acadia Pharmaceuticals ACAD Maintain Overweight
(N/A)
 
 
  Details
2/11/2022 Ultragenyx Pharma RARE Upgrade Overweight
(Neutral)
74.75
(48.29)
-35.4% Details
1/27/2022 Vertex VRTX Maintain Overweight
(N/A)
 
 
  Details
1/5/2022 Cerevel Therapeutics CERE New Coverage Overweight
(N/A)
34.49
(33.42)
-3.1% Details
11/19/2021 bluebird bio BLUE Maintain Neutral
(N/A)
 
 
  Details
11/19/2021 Legand Biotech Corp. LEGN Maintain Overweight
(N/A)
 
 
  Details
10/28/2021 NovoCure Ltd. NVCR Maintain Neutral
(N/A)
 
 
  Details
9/30/2021 Karuna Therapeutics Inc. KRTX New Coverage Overweight
(N/A)
118.69
(267.25)
125.17% Details
8/9/2021 bluebird bio BLUE Maintain Neutral
(N/A)
 
 
  Details
8/5/2021 Sana Biotechnology SANA Maintain Neutral
(N/A)
 
 
  Details
8/5/2021 Acadia Pharmaceuticals ACAD Maintain Overweight
(N/A)
 
 
  Details
7/28/2021 Alkermes ALKS Maintain Neutral
(N/A)
 
 
  Details
7/22/2021 Biogen BIIB Maintain Neutral
(N/A)
 
 
  Details
7/20/2021 Moderna MRNA Maintain Neutral
(N/A)
 
 
  Details
6/11/2021 Biogen BIIB Maintain Neutral
(N/A)
 
 
  Details
6/1/2021 Amgen AMGN Maintain Neutral
(N/A)
 
 
  Details
5/11/2021 BioNTech BNTX Maintain Neutral
(N/A)
 
 
  Details
3/1/2021 Sana Biotechnology SANA New Coverage Neutral
(N/A)
32.05
(6.70)
-79.1% Details
2/25/2021 Moderna MRNA Maintain Neutral
(N/A)
 
 
  Details
2/25/2021 Editas Medicine EDIT Downgrade Underweight
(Neutral)
49.70
(14.97)
-69.88% Details
2/17/2021 bluebird bio BLUE Downgrade Neutral
(Overweight)
45.76
(5.85)
-87.22% Details
2/12/2021 Ultragenyx Pharma RARE Downgrade Neutral
(Overweight)
162.78
(48.29)
-70.33% Details
2/11/2021 Alkermes ALKS Maintain Neutral
(N/A)
 
 
  Details
2/5/2021 Regeneron Pharma REGN Maintain Neutral
(N/A)
 
 
  Details
8/19/2020 BioMarin Pharmaceutical Inc. BMRN Maintain Overweight
(N/A)
 
 
  Details
8/13/2020 Moderna MRNA Maintain Neutral
(N/A)
 
 
  Details
8/11/2020 BioNTech BNTX Maintain Neutral
(N/A)
 
 
  Details
8/5/2020 Regeneron Pharma REGN Maintain Neutral
(N/A)
 
 
  Details
8/5/2020 Allogene ALLO Maintain Neutral
(N/A)
 
 
  Details
8/4/2020 Incyte INCY Maintain Neutral
(N/A)
 
 
  Details
7/30/2020 Alexion Pharmaceuticals ALXN Maintain Overweight
(N/A)
 
 
  Details
7/30/2020 NovoCure Ltd. NVCR Maintain Neutral
(N/A)
 
 
  Details
7/20/2020 Moderna MRNA Downgrade Neutral
(Overweight)
94.85
(145.66)
53.57% Details
7/1/2020 Legand Biotech Corp. LEGN New Coverage Overweight
(N/A)
41.10
(45.34)
10.32% Details
5/11/2020 bluebird bio BLUE Maintain Overweight
(N/A)
 
 
  Details
5/6/2020 Incyte INCY Downgrade Neutral
(Overweight)
100.99
(73.87)
-26.85% Details
5/5/2020 Regeneron Pharma REGN Maintain Neutral
(N/A)
 
 
  Details
5/1/2020 Gilead Sciences GILD Downgrade Neutral
(Overweight)
84.00
(65.34)
-22.21% Details
3/26/2020 bluebird bio BLUE Maintain Overweight
(N/A)
 
 
  Details
3/18/2020 BioNTech BNTX Downgrade Neutral
(Overweight)
40.00
(146.22)
265.55% Details
2/26/2020 Moderna MRNA Maintain Overweight
(N/A)
 
 
  Details
2/14/2020 Alkermes ALKS Maintain
(N/A)
 
 
  Details
2/14/2020 Alkermes ALKS Downgrade Neutral
(Overweight)
19.10
(25.27)
32.3% Details
11/4/2019 BioNTech BNTX New Coverage Overweight
(N/A)
16.82
(146.22)
769.32% Details
10/24/2019 Acorda Therapeutics, Inc. ACOR Downgrade Underweight
(Neutral)
2.42
(0.46)
-80.99% Details
10/23/2019 Alkermes ALKS Maintain Overweight
(N/A)
 
 
  Details
9/10/2019 Acadia Pharmaceuticals ACAD Maintain Overweight
(N/A)
 
 
  Details
7/26/2019 NovoCure Ltd. NVCR Downgrade Neutral
(Overweight)
70.99
(78.17)
10.11% Details
5/7/2019 GW Pharma GWPH Maintain Overweight
(N/A)
 
 
  Details
3/21/2019 Biogen BIIB Downgrade Neutral
(Overweight)
320.59
(214.07)
-33.23% Details
1/2/2019 Moderna MRNA New Coverage Overweight
(N/A)
15.27
(94.85)
521.15% Details
1/2/2019 GW Pharma GWPH New Coverage Overweight
(N/A)
97.39
(218.96)
124.83% Details
11/14/2018 Jounce Therapeutics JNCE Downgrade Underweight
(Neutral)
4.46
(4.83)
8.3% Details
11/2/2018 Puma Biotechnology PBYI Downgrade Underweight
(Neutral)
38.60
(3.11)
-91.94% Details
10/31/2018 Clovis Oncology CLVS Downgrade Neutral
(Overweight)
16.70
(1.40)
-91.62% Details
10/2/2018 Clovis Oncology CLVS Maintain Overweight
(N/A)
 
 
  Details
8/29/2018 Ultragenyx Pharma RARE Maintain Overweight
(N/A)
 
 
  Details